CorMedix Has $355 Million of Cash and a $58 Million Enterprise Value
The 2027 DefenCath reimbursement floor that management spent four quarters promising quietly became a deferral — and the Heron deal is the answer to a question investors had not finished asking.
CRMD · Earnings Call · 2026-11-12
The Cliff, Minus the Makeup
CorMedix reported third-quarter revenue of $54.5 million against $104.3 million a year ago, and adjusted EBITDA of $3.1 million against $71.9 million. Those are the headline numbers. The more revealing number is buried one level down: DefenCath revenue was $17.2 million, but $5 million of that was a favorable change in estimate on Medicaid rebate and product return allowances. The underlying quarterly run rate is closer to $12 million. This is not a one-off. A favorable change in estimate now sits near the top of the company's keyword rankings for the first time — but the mechanic has quietly become a recurring feature, following the $9 million "good guy" in the first quarter and a similar true-up in the second. Serge Belanger of Needham asked the question nobody else wanted to: with $5 million of the $17.2 million coming from an allowance release, should investors think of $12 million as the base going forward? Joe Todisco's answer was one word of qualification and one of confirmation: “tentatively, yes. I think it would be a little bit of a notch up but that is probably the right way to look at it.” — Joseph Todisco, Chairman and Chief Executive Officer · 2026-11-12 That is the entire quarter in miniature. A ~$12 million-per-quarter product has replaced one that was running north of $90 million. Total revenue has gone from $129 million to $102 million to $54.5 million across three quarters, and gross margin has compressed from a 95.4% peak to 75.7%. The product did not lose patients — the price did.The Floor That Vanished
For four consecutive quarters, management sold investors a specific form of comfort: a floor under 2027. In March, Todisco framed it as a promise of durability — “we wanted to give investors comfort that there is at least a base business level of DEFENCATH, which we expect to see price appreciation and hopefully stable volumes” — Joseph Todisco, Chairman and Chief Executive Officer · 2026-03-05. In May he went further, with a stated ambition to revise upward: “Right now, I think I'm comfortable saying we're affirming the guidance we put out previously for 2027... would love to be in a position later this year, early next year to take that guidance upwards.” — Joseph Todisco, Chairman and Chief Executive Officer · 2026-05-14 Seven months later, the floor is gone.The mechanism behind the retreat is the post-TDAPA arithmetic. CMS finalized a quarterly reset, beginning at $8.30 for the first quarter of 2027. Management expects every quarter of 2027 to clear today's $2.37 rate and the full-year average to land at something like double it — but also concedes the annual average will be below $8.32. The critical, under-appreciated wrinkle: the quarterly reset is fed by utilization and pricing data only CorMedix possesses. “We have not shared that data with any customer or third party, we believe third party projections of the quarterly path are subject to significant uncertainty.” — Joseph Todisco, Chairman and Chief Executive Officer · 2026-11-12 The company is, literally, the sole source of the inputs that determine its own reimbursement. Todisco's explanation — that CMS uses the timing of rebate payments rather than accruals, and that long-dated volume-incentive rebates will land in different periods than financial statements imply — is a real accounting point, and also a warning that sell-side models built off the income statement will be wrong in both directions. The offset is Medicare Advantage, where the contractual framework is described as "largely final" but operationalization is not — the aircraft-carrier metaphor returns verbatim from prior calls. Until then, fee for service patients is now the company's single highest-ranked keyword, which is itself telling: the narrative has moved from growth to retention of a shrinking, price-reset population.In that regard, we are deferring 2027 DefenCath guidance at this time and anticipate being able to update investors in early 27.